Cannabis for Tourette Tics: What the Meta-Analysis Does and Does Not Prove
A 2026 systematic review and meta-analysis reported reductions in tic severity and premonitory urges with cannabis-based medicines in Tourette syndrome. The signal is promising, but the evidence base is still small, mixed, and not enough to settle…
Cannabinoids for Alzheimer’s Agitation: What a New Meta-Analysis Adds
A new systematic review and meta-analysis found lower agitation and neuropsychiatric symptom scores with cannabinoid-based therapies in Alzheimer’s disease, but the evidence remains limited by small trials, heterogeneous products, short follow-up, and…
Oral CBD and Blood Pressure: What a New Systematic Review Really Shows
A June 2026 systematic review examined whether oral CBD changes blood pressure in adults. The signal is interesting, especially under stress and during sleep, but the trials were small, short, and too heterogeneous to treat CBD as a blood-pressure…
CED Cannabis Science Digest: Immune Activation and CB1-Target Insights
This digest highlights immune activation cannabis research focusing on HIV-linked inflammatory signaling, CB1-target drug design hurdles, and preclinical CBD brain delivery. These three verified cannabis science signals clarify current evidence limits…
CED Cannabis Science Digest: 3 Sleep, Oncology, and Pain Cannabis Signals Worth Watching
This digest highlights 3 verified cannabis science signals focusing on sleep, oncology communication, and pain research. These signals provide valuable insights for clinicians and researchers. They emphasize the importance of product type, patient…
CED Cannabis Science Digest: 3 Clinical-Caution Cannabis Signals Worth Watching
This digest highlights 3 clinical-caution cannabis signals from recent studies, focusing on safety and efficacy limits. The signals include a negative CB1 trial, FAAH translational challenges, and weak PTSD evidence. These findings help clinicians set…
CED Cannabis Science Digest: 3 Early Therapeutic Cannabinoid Signals Worth Watching
This digest highlights three early therapeutic cannabinoid signals in Alzheimer's disease, pain-pathway drug design, and CBD use in sickle cell disease. These signals represent promising directions in cannabinoid therapeutic research. While not yet…
CED Cannabis Science Digest: 3 Public-Health Cannabis Signals Worth Watching
This digest highlights cannabis public health signals 2026, focusing on pregnancy outcomes, psychosis follow-up, and e-scooter road safety. These signals refine clinical counseling and screening. The evidence supports more specific risk conversations…
Cannabis Enforcement Policy Meetings: June 2026 Updates
This update covers cannabis enforcement policy meetings held in June 2026, highlighting key regulatory developments. These meetings influence enforcement actions and legal frameworks. Clinicians should stay informed about cannabis enforcement policy…
CED Cannabis Science Digest: 3 CBD and Cannabis Safety Signals Worth Watching
This digest highlights three verified CBD blood pressure safety signals alongside cannabis safety concerns in 2026 research. It covers oral CBD effects on blood pressure, CBD and alcohol co-use safety, and vaping-related lung risks. These signals provide…
